Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.23

€1.23

-1.610%
-0.02
-1.610%
-
 
15.05.24 / Tradegate WKN: A2QEUC / Name: Marinus Pharmaceuticals Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Marinus Pharmaceuticals Inc. Stock

We can see a decrease in the price for Marinus Pharmaceuticals Inc.. Compared to yesterday it has lost -€0.020 (-1.610%).
Our community identified positive and negative aspects for Marinus Pharmaceuticals Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Marinus Pharmaceuticals Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.

Pros and Cons of Marinus Pharmaceuticals Inc. in the next few years

Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program: https://mms.businesswire.com/media/20240405633110/en/2090706/5/marinus-color-R.jpg
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program


Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results: https://mms.businesswire.com/media/20240405633110/en/2090706/5/marinus-color-R.jpg
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results


Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and

Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference: https://mms.businesswire.com/media/20240405633110/en/2090706/5/marinus-color-R.jpg
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference


Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein